Alerts will be sent to your verified email
Verify Email
ASTONEALAB
|
Astonea Labs
|
Beta Drugs
|
|
|---|---|---|
|
Operational Metrics
|
||
|
Financials
|
||
|
5 yr Average ROE
|
14.43 % | 21.73 % |
|
5yr average Equity Multiplier
|
7.23 | 1.75 |
|
5yr Average Asset Turnover Ratio
|
0.87 | 1.04 |
|
5yr Avg Net Profit Margin
|
2.19 % | 11.97 % |
|
Price to Book
|
0.0 | 0.0 |
|
P/E
|
37.37 | 119.88 |
|
5yr Avg Cash Conversion Cycle
|
64.4 Days | 15.7 Days |
|
Inventory Days
|
81.88 Days | 43.83 Days |
|
Days Receivable
|
101.3 Days | 87.61 Days |
|
Days Payable
|
173.44 Days | 113.94 Days |
|
5yr Average Interest Coverage Ratio
|
1.85 | 13.71 |
|
5yr Avg ROCE
|
14.81 % | 27.85 % |
|
5yr Avg Operating Profit Margin
|
14.98 % | 21.58 % |
|
5 yr average Debt to Equity
|
3.96 | 0.23 |
|
5yr CAGR Net Profit
|
72.42 % | 31.07 % |
|
5yr Average Return on Assets
|
2.07 % | 12.53 % |
|
Shareholdings
|
||
|
Promoter Holding
|
n/a | 66.73 % |
|
Share Pledged by Promoters
|
n/a | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
n/a | 0.02 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
n/a | 0.0 |
|
Astonea Labs
|
Beta Drugs
|
|
|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|